Advertisement

Tumor Biology

, Volume 36, Issue 10, pp 7667–7674 | Cite as

HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma

  • Abdelfattah M. Attallah
  • Mohamed El-Far
  • Camelia A. Abdel Malak
  • Mohamed M. Omran
  • Gamal E. Shiha
  • Khaled Farid
  • Lamiaa A. Barakat
  • Mohamed S. Albannan
  • Ahmed A. Attallah
  • Mohamed A. Abdelrazek
  • Mohamed S. Elbendary
  • Refaat Sabry
  • Gehan A. Hamoda
  • Mohamed M. Elshemy
  • Abdallah A. Ragab
  • Basma M. Foda
  • Sanaa O. Abdallah
Research Article

Abstract

Currently, the search for suitable hepatocellular carcinoma (HCC) biomarkers is very intensive. Besides, efficacy and cost/effectiveness of screening and surveillance of cirrhotics for the diagnosis of HCC is still debated. So, the present study is concerned with the evaluation of cytokeratin-1 (CK-1) and nuclear matrix protein-52 (NMP-52) for identifying HCC. Two-hundred and eighty individuals categorized into three groups [liver fibrosis (F1–F3), cirrhosis (F4), and HCC] constituted this study. Western blot was used for identifying CK-1 and NMP-52 in serum samples. As a result, a single immunoreactive band was shown at 67 and 52 kDa corresponding to CK-1 and NMP-52, respectively. Both CK-1 and NMP-52 bands were cut and electroeluted separately. These markers were quantified in sera using ELISA. Patients with HCC were associated with higher concentrations of CK-1 and NMP-52 than those without HCC with a significant difference (P < 0.0001). CK-1 showed an area under receiver-operating characteristic curve (AUC) of 0.83 with 75 % sensitivity and 82 % specificity while NMP-52 yielded 0.72 AUC with 62 % sensitivity and 70 % specificity for identifying HCC. HCC-DETECT comprising CK-1 and NMP-52 together with AFP was then constructed yielding 0.90 AUC for identifying HCC with 80 % sensitivity and 92 % specificity. HCC-DETECT was then tested for separating HCC from F1–F3 showing 0.94 AUC with 80 % sensitivity and 93 % specificity. In conclusion, CK-1 in conjunction with NMP-52 and AFP could have a potential role for improving the detection of HCC with a high degree of accuracy.

Keywords

Liver diseases Serum biomarkers HCC-DETECT Western blot 

Notes

Conflicts of interest

None.

References

  1. 1.
    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep. 2010;12:186–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15:297–306.CrossRefPubMedGoogle Scholar
  6. 6.
    Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55:2744–55.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson PJ. Screening for hepatocellular carcinoma—answers to some simple questions. Am J Gastroenterol. 2002;97:225–6.PubMedGoogle Scholar
  8. 8.
    Lin DY, Liaw YF. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 2001;16:715–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34:603–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Shimizu Y, Nakano I, Katano Y, Shimizu H, Fukuda Y. Clinical implications of measurement of serum nuclear matrix protein levels in patients with liver disease. Hepatogastroenterology. 2005;52:1809–13.PubMedGoogle Scholar
  12. 12.
    Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun. 1974;60:1410–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 1989;49:2525–32.PubMedGoogle Scholar
  14. 14.
    Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009;11:R39.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Moll R. Cytokeratins as markers of differentiation. Expression profiles in epithelia and epithelial tumors. Veroff Pathol. 1993;142:1–197.PubMedGoogle Scholar
  16. 16.
    Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta. 2011;412:2031–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol. 2009;15:4387–91.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18—the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009;30:1103–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Attallah AM, El-Far M, Abdel Malak CA, Zahran F, Farid K, Omran MM, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2011;412:2310–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRefPubMedGoogle Scholar
  22. 22.
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350–4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.PubMedGoogle Scholar
  25. 25.
    Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39:434–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Cui R, He J, Zhang F, Wang B, Ding H, Shen H, et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003;88:1878–82.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36:S84–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol. 2012;2012:859076.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Apaydin R, Gurbuz Y, Bayramgurler D, Bilen N. Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study. Amyloid. 2005;12:41–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim MA, Lee HS, Yang HK, Kim WH. Cytokeratin expression profile in gastric carcinomas. Hum Pathol. 2004;35:576–81.CrossRefPubMedGoogle Scholar
  32. 32.
    Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403–39.CrossRefPubMedGoogle Scholar
  33. 33.
    D’Errico A, Baccarini P, Fiorentino M, Ceccarelli C, Bonazzi C, Ponzetto A, et al. Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection. Hum Pathol. 1996;27:599–604.CrossRefPubMedGoogle Scholar
  34. 34.
    Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev. 2007;33:230–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.CrossRefPubMedGoogle Scholar
  36. 36.
    Hughes JH, Cohen MB. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am J Clin Pathol. 1999;111:267–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–801.CrossRefPubMedGoogle Scholar
  38. 38.
    Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Llovet JM, Bruix J, Fuster J, Castells A, Garcia‐Valdecasas JC, Grande L, et al. Liver transplantation for small hepatocellular carcinoma: the tumor‐node‐metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Ishida H, Matsuo S, Inoue Y. Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up. Rinsho Byori. 2010;58:1065–72.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Abdelfattah M. Attallah
    • 1
  • Mohamed El-Far
    • 2
  • Camelia A. Abdel Malak
    • 3
  • Mohamed M. Omran
    • 4
  • Gamal E. Shiha
    • 5
  • Khaled Farid
    • 5
  • Lamiaa A. Barakat
    • 6
  • Mohamed S. Albannan
    • 1
  • Ahmed A. Attallah
    • 1
  • Mohamed A. Abdelrazek
    • 1
  • Mohamed S. Elbendary
    • 1
  • Refaat Sabry
    • 3
  • Gehan A. Hamoda
    • 1
  • Mohamed M. Elshemy
    • 1
  • Abdallah A. Ragab
    • 1
  • Basma M. Foda
    • 1
  • Sanaa O. Abdallah
    • 7
  1. 1.Biotechnology Research CenterNew DamiettaEgypt
  2. 2.Faculty of ScienceMansoura UniversityMansouraEgypt
  3. 3.Faculty of ScienceDamietta UniversityMansouraEgypt
  4. 4.Faculty of ScienceHelwan UniversityCairoEgypt
  5. 5.Faculty of MedicineMansoura UniversityMansouraEgypt
  6. 6.Faculty of SciencePort-Said UniversityPort-SaidEgypt
  7. 7.Faculty of ScienceCairo UniversityGizaEgypt

Personalised recommendations